Blog

Internasal Herpes Vaccine

A company called Blue Willow Biologicals recently received a patent for a novel Herpes Simplex 1 and 2 vaccine that both protects and has mherapuetic value. This is an exciting development as protection from Herpes Simplex and a therapuetic vaccine have proved elusive. I have reprinted the press release below:

BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine

accine Expected to Deliver Therapeutic and Preventive Protection

ANN ARBOR, Mich., (July 23, 2019) – BlueWillow Biologics® today announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the development of an intranasal NanoVax® herpes simplex virus (HSV) vaccine. The patent protects the use of BlueWillow’s unique NanoVax adjuvant platform in the development of a vaccine that provides protection against HSV-1 and HSV-2, the two viruses that can cause genital herpes.

More than one in six people aged 14–49 are infected with genital herpes and an estimated 776,000 new infections occur annually, according to the Centers for Disease Control and Prevention (CDC). Genital herpes increases a person’s risk of contracting HIV and can lead to miscarriage and premature birth in infected pregnant women. Herpes can also be passed from the mother to child during birth, potentially resulting in neonatal herpes, a fatal infection. Most genital herpes vaccine candidates have failed or been abandoned in recent years, leaving no reliable therapeutic or preventive vaccine for the disease.

BlueWillow’s intranasal NanoVax platform elicits both mucosal and systemic immunity through its novel oil-in-water nanoemulsion (NE) adjuvant, offering a unique advantage to combat sexually transmitted infections (STIs) including genital herpes. The mucosal immunity elicited by intranasal NE vaccines provides critical protection against infections at the port of entry by which a pathogen enters the body.

The intranasal NanoVax HSV vaccine has demonstrated safety and efficacy in both prophylactic and therapeutic animal models for genital herpes. In a prophylactic guinea pig study, the intranasal vaccine prevented genital herpes infection in 92 percent of animals vaccinated. Therapeutic study animals previously infected with genital herpes who received the BlueWillow vaccine reduced recurrent lesions and viral shedding by more than 50 percent compared to animals who received no treatment.

“Genital herpes is easily and often unknowingly transmitted between partners. The lifelong infection frequently causes psychological distress and negatively impacts quality of life,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, BlueWillow. “After years of research in animals, we are moving closer to studies in humans where we expect results to validate the potential of this much-needed vaccine.”

About BlueWillow

BlueWillow Biologics® is a privately-held biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on developing and commercializing vaccines using its patented NanoVax® technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination and can elicit both mucosal and systemic immunity when applied intranasally.

BlueWillow is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia, as well as vaccines for selected allergic conditions. Visit BlueWillow.com for details on the company’s vaccine pipeline and studies completed to date.

THE MASQUE OF ANARCHY BY THE ENGLISH POET SHELLY IS AN EARLY CALL TO NONVIOLENT RESISTANCE FOLLOWING THE PETERLOO MASSACRE ON 16 August 1819 IN ENGLAND.

 

“Stand ye calm and resolute,
Like a forest close and mute,
With folded arms and looks which are
Weapons of unvanquished war.

And if then the tyrants dare,
Let them ride among you there;
Slash, and stab, and maim and hew;
What they like, that let them do.

With folded arms and steady eyes,
And little fear, and less surprise,
Look upon them as they slay,
Till their rage has died away:

Then they will return with shame,
To the place from which they came,
And the blood thus shed will speak
In hot blushes on their cheek:

Rise, like lions after slumber
In unvanquishable number!
Shake your chains to earth like dew
Which in sleep had fallen on you:

“Rise, like lions after slumber
In unvanquishable number!
Shake your chains to earth, like dew
Which in sleep had fallen on you:
Ye are many—they are few!”
Ye are many—they are few!”

 

Cuba reports that the Men B vaccine protects against gonorrhoea. Similar results have previously been reported from New Zealand as well.

Neisseria meningitidis and Neisseria gonorrhoeae share between 80% and 90% of their genetic sequence. Meningococcal serogroup B vaccines based on outer membrane vesicles-such as VA-MENGOC-BC-could cross-protect against gonorrhea. The aim of this study was to analyze the incidence rates of gonorrhea and other sexually transmitted diseases with respect to the use of the VA-MENGOC-BC vaccine.

Health statistics between 1970 and 2017 were reviewed and the incidence of meningococcal disease and sexually transmitted diseases (gonorrhea, syphilis, condyloma acuminatum , hepatitis B and human immunodeficiency virus infection) were analyzed during the pre- and post-vaccination periods.

Gonorrhea incidence was also analyzed by age groups. Results: VA-MENGOC-BC was successfully used to control a meningococcal epidemic in Cuba. The strategy to combat the epidemic was carried out in two stages. The first one was a nationwide mass-vaccination campaign from 1989 to 1990, targeting the population at highest-risk aged 3 months to 24 years. During the second stage, begun in 1991, it was included in the Expanded Immunization Program. Gonorrhea incidence increased from 1970 to 1989. However, after the VA-MENGOC-BC massive vaccination campaign a sharp decrease of gonorrhea incidence was observed. It lasted between 1989 and 1993. A second incidence peak was detected in 1995, but it dropped again. Data clearly show a decline in the incidence of gonorrhea following massive vaccination, in contrast with other sexually transmitted diseases. Incidence rates in unvaccinated age groups also decreased, probably due to herd immunity. Conclusion: There is evidence that VA-MENGOC-BC could induce a moderate protection against gonorrhea.

See Clinical and Experimental Vaccine Research. 2019 Jul; 8 (2) : 110-115.

A meningococcal B vaccine induces cross-protection against gonorrhea.

Rolando Felipe Ochoa Azze

PMID: 31406692

Interesting article excerpted below on vaccination causing flare ups in gout patients.

Vaccination may increase gout flare risk

medwireNews: The increased risk for gout flares following receipt of the aluminum-free recombinant zoster vaccine (RZV) is not unique to this vaccine but is instead associated with vaccination in general, regardless of the adjuvant used, US researchers report.

However, Hyon Choi (Massachusetts General Hospital, Boston) and colleagues stress that “the absolute magnitude of increased odds of gout flares with vaccinations remains small.”

The researchers explain that although RZV is “the preferred zoster vaccine endorsed by the Advisory Committee on Immunization Practices,” two phase III clinical trials have shown that it is associated with a 3.6-fold increased risk for gout flares, prompting the implementation of an enhanced post marketing surveillance program.

Trump’s NLRB Members Force Adoption of New Rule Attacking Unions.

The National Labor Relation Board (NLRB) has taken a broad step towards doing away with unions in America that upsets the current collective bargaining and union recognition system. Employers can now announce a pending withdrawal of recognition within 90 days of the contract expiration and withdraw when the collective bargaining agreement ends. The Union then has 45 days to file a petition for a new election. This was a 3-1 decision based on Johnson Control’s Inc. anticipatory withdrawal of recognition to a UAW affiliate that represented 160 of its workers. (NLRB 10-CA-151843 7/3/19) In overturning portions of the 2001 ruling in Levitz Furniture, the NLRB said this ruling protected employee free choice and that it would apply the new framework retroactively. The NLRB is also considering changes to other restrictions on elections to decertify . The new decision allows the employer to cease bargaining with a union and question its majority status 90 days prior to the expiration of a contract and to unilaterally force the union to once again go through an election to prove its majority status in the workplace. This decision completely upends the union representational scheme that has brought labor peace in the workplace.

Many employees will likely loose union representation and power at the bargaining table. On the plus side, the new system will force unions into a more adversary relationship and force those unions who currently do little in the workplace between contracts to become more active in order to actually maintain majority status. But this is clearly an attack on organized labor and reflects the current lack of organization in the workplaces of America. Less than 30 percent of American workers are organized and those that are come largely from the public sector. This lack of organization by labor in the USA is what makes the governmental leaders feel free to take a stab at labor. Our response will determine weather this attack proves fatal.

War and Peace

The Trump administration has turned their
attacks on the Venezuela government into a full fledged embargo. Besides being uncalled for it is going to be no more successful then the embargo on Cuba. What it will do is cause unnecessary death and suffering by the people of Venezuela . The policy is a desperate attempt by the United States to control Venezuelan oil fields in order to ensure a steady supply of oil so that the United States can wage the war against Iraq that is being pushed by the neofascist, John Bolton, who is President Trump’s National Security advisor. Russia’s leader, Putin, famously asked John Bolton if he had removed the olive branches from the American seal. Those who advocate war lingering whether the Bolton’s or Hillary Clinton deserve the dust bins of history.

U.S. sanctions in Venezuela result in untold suffering and the death of 40’000 people

We must resist the United State’s attempts to dictate to the people of Venezuela . We have appropriated the Venezuela government ownership of Chevron Oil and other assists of their people simply because we desire complete control of their oil and other natural resources and because we refuse to let stand any government that serves its people better than we do. This is an economic and political war by United States corporate interests against the poor who struggle for a better life in their own country. The imperial desires of the United States can not be allowed to stand. Those U.S. corporate interests bring nothing but death and destruction both here and abroad.

How many die in America because we lack national health insurance? People here are dying because insulin that is $30 dollars in Canada is $300 in the United States. An Epipen that costs next ro nothing now sells for hundreds of dollars in America. Corporate interests put profit above human life.

We need to end capitalism with its exploitation at home and its wars for economic hegemony abroad .

A company called Blue Willow Biologicals has received a patent on a novel nasal vaccine that protects against Herpes Simplex 1 and 2 and has therapuetic value as well in those already infected.

The announcement by Blue Willow Bio9logicals of their novel patent for Herpes vaccine is reprinted below:

Vaccine Expected to Deliver Therapeutic and Preventive Protection

ANN ARBOR, Mich., (July 23, 2019) – BlueWillow Biologics® today announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the development of an intranasal NanoVax® herpes simplex virus (HSV) vaccine. The patent protects the use of BlueWillow’s unique NanoVax adjuvant platform in the development of a vaccine that provides protection against HSV-1 and HSV-2, the two viruses that can cause genital herpes.

More than one in six people aged 14–49 are infected with genital herpes and an estimated 776,000 new infections occur annually, according to the Centers for Disease Control and Prevention (CDC). Genital herpes increases a person’s risk of contracting HIV and can lead to miscarriage and premature birth in infected pregnant women. Herpes can also be passed from the mother to child during birth, potentially resulting in neonatal herpes, a fatal infection. Most genital herpes vaccine candidates have failed or been abandoned in recent years, leaving no reliable therapeutic or preventive vaccine for the disease.

BlueWillow’s intranasal NanoVax platform elicits both mucosal and systemic immunity through its novel oil-in-water nanoemulsion (NE) adjuvant, offering a unique advantage to combat sexually transmitted infections (STIs) including genital herpes. The mucosal immunity elicited by intranasal NE vaccines provides critical protection against infections at the port of entry by which a pathogen enters the body.

The intranasal NanoVax HSV vaccine has demonstrated safety and efficacy in both prophylactic and therapeutic animal models for genital herpes. In a prophylactic guinea pig study, the intranasal vaccine prevented genital herpes infection in 92 percent of animals vaccinated. Therapeutic study animals previously infected with genital herpes who received the BlueWillow vaccine reduced recurrent lesions and viral shedding by more than 50 percent compared to animals who received no treatment.

“Genital herpes is easily and often unknowingly transmitted between partners. The lifelong infection frequently causes psychological distress and negatively impacts quality of life,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, BlueWillow. “After years of research in animals, we are moving closer to studies in humans where we expect results to validate the potential of this much-needed vaccine.”

About BlueWillow

BlueWillow Biologics® is a privately-held biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on developing and commercializing vaccines using its patented NanoVax® technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination and can elicit both mucosal and systemic immunity when applied intranasally.

BlueWillow is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia, as well as vaccines for selected allergic conditions. Visit BlueWillow.com for details on the company’s vaccine pipeline and studies completed to date.

An Old Vaccine Keeps Getting Better — From: Precision Vaccinations

An Old Vaccine Keeps Getting Better

Bacille Calmette-Guerin (BCG) vaccine enhances bacteria protection and appears to last longer

July 22nd, 2019 – New research about an old vaccine showed once again how effective it is, but also suggests the Bacille Calmette-Guerin (BCG) vaccine improves our immune response to a wider range of bacteria than originally intended.

A new study published on July 12, 2019, by the University of Otago, Wellington, found the BCG vaccine, which has been in use since 1921, gave stronger protection and appeared to last far longer than previously thought.

Previous studies have given widely different results on the effectiveness of BCG and its effectiveness had been questioned in the past, said Principal investigator Dr. Ayesha Verrall, who is also an infectious diseases physician at Wellington Hospital, in a press release.

“Our research has shown that the people who remained uninfected were truly immune, and not just lucky and uninfected. This is also supported by the fact they have stronger innate immune

“We also found this protection was associated with stronger innate immune responses to a range of different bacteria, suggesting BCG protects people by ‘training’ their innate immune cells.”

“This is different from how vaccines are conventionally thought to work, through inducing memory cells to make antibodies that are highly specific to a particular bacteria.”

“Our finding that the BCG vaccine appears to work through the innate immune system is consistent with it having broader benefits than just TB protection. These non-specific effects are really interesting and need further study.”

According to the World Health Organization, approximately 1.7 billion people—23 percent of the world’s population—have latent TB infection and carry the risk of developing TB during their lifetime.

Tuberlucious vaccines

The BCG vaccine is not widely used in the United States, but it is often given to infants and small children in other countries where TB is common, says the US Centers for Disease Control and Prevention (CDC).

In the United States, BCG should be considered for only very select people who meet specific criteria and in consultation with a TB expert. Healthcare providers who are considering BCG vaccination for their patients are encouraged to discuss this intervention with the TB control program in their area.

In the USA, the BCG vaccination should only be considered for children who have a negative TB test and who are continually exposed and cannot be separated from adults who:

Are untreated or ineffectively treated for TB disease, and the child cannot be given long-term primary preventive treatment for TB infection; or

Have TB disease caused by strains resistant to isoniazid and rifampin.

Future tuberculosis vaccines would ideally target both M. tuberculosis-infected and uninfected adolescents and adults said these researchers.

Dr. Verrall is about to start a new field study to see if BCG vaccination works by adding chemical marks to innate immune cells’ DNA, leading to a “boost” for innate immune responses. This new work is funded by the New Zealand Health Research Council.

The research was part of a long-standing collaboration on TB between the University of Otago’s Centre for International Health, Universitas Padjadjaran, and Radboud University.